COMMUNIQUÉS West-GlobeNewswire

Jupiter Neurosciences Unveils Nugevia™ GLO: A Breakthrough in Cellular Skin Health, Backed by Patented Pharmaceutical Science
27/06/2025
GLO targets the growing ”beauty-from-within” market with scientifically proven cellular defense and skin vitality benefits Jupiter, Florida, June 27, 2025 (GLOBE NEWSWIRE) -- Jupiter Neurosciences, Inc. (NASDAQ: JUNS [...]
Calidi Biotherapeutics Announces Shareholder Letter from CEO
27/06/2025
SAN DIEGO, June 27, 2025 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics Inc. (NYSE American: CLDI) (“Calidi”), a clinical-stage biotechnology company pioneering the development of systemic oncolytic targeted immunotherapies [...]
Autonomix Medical, Inc. Granted New U.S. Patent for Innovative Catheter-Based Platform Technology
27/06/2025
Patent supports the Company’s broader mission to advance minimally invasive, nerve-focused treatments across high-need indications Strengthens strategic position in a multi-billion-dollar market opportunity and expands [...]
CorMedix Inc. Announces Pricing of Public Offering of Common Stock
27/06/2025
BERKELEY HEIGHTS, N.J., June 27, 2025 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and [...]
Lyra Therapeutics Announces Up to Approximately $15 Million Registered Direct Offering and Concurrent Private Placement Priced At-The-Market Under Nasdaq Rules
27/06/2025
Upfront Gross Proceeds of $5.0 Million, with Up to Approximately $9.8 Million of Additional Gross Proceeds Assuming the Cash Exercise in Full of Private Placement Warrants WATERTOWN, Mass., June 27, 2025 (GLOBE NEWSWIRE [...]
Ultragenyx Receives Breakthrough Therapy Designation for GTX-102 in Angelman Syndrome
27/06/2025
Phase 3 Aspire study enrollment on track to complete in 2025 Aurora study to evaluate GTX-102 in other Angelman syndrome genotypes and ages expected to initiate later this year NOVATO, Calif., June 27, 2025 (GLOBE [...]
Results of Annual General Meeting
27/06/2025
June 27, 2023 Biodexa Pharmaceuticals PLC (“ Biodexa ” or the “ Company ”) Results of Annual General Meeting Biodexa Pharmaceuticals PLC (NASDAQ: BDRX), a clinical stage biopharmaceutical company developing a pipeline [...]
Helius Medical Technologies Announces Reverse Stock Split
27/06/2025
NEWTOWN, Pa., June 27, 2025 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (Nasdaq:HSDT) (“Helius” or the “Company”), a neurotech company focused on delivering a novel therapeutic neuromodulation approach for [...]
VigRX Organic Bio Maca Supplement: Experts Discuss Science Behind Beginner’s Guide to Choose Best Maca Root Supplement For Men & Women
27/06/2025
Discover why VigRX Organic Bio Maca is being recognized in 2025 as the best maca root supplement for men and women. Explore its energy, mood, and hormonal balance benefits. Limassol, Cyprus, June 27, 2025 (GLOBE [...]
Kratom Brand, Happy Go Leafy Announces 2025 Product Line Featuring New Strains for Pain Relief, Energy, and Mood Enhancement
27/06/2025
Check out Happy Go Leafy’s new 2025 Kratom strains offering pain relief, energy, and mood enhancement. Miami, Florida, June 27, 2025 (GLOBE NEWSWIRE) -- Kratom, a tropical tree native to Southeast Asia, has been gaining [...]
Clearmind Medicine Expands Global Clinical Trial Targeting Multibillion-Dollar Alcohol Use Disorder Market
27/06/2025
Vancouver, Canada, June 27, 2025 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the "Company"), a clinical-stage biotech company focused on discovery and development of novel [...]
ALPHA PRO TECH, LTD. ANNOUNCES $2 MILLION EXPANSION OF SHARE REPURCHASE PROGRAM
27/06/2025
NOGALES, Ariz., June 27, 2025 (GLOBE NEWSWIRE) -- – Alpha Pro Tech, Ltd. (NYSE American: APT) , a leading manufacturer of products designed to protect people, products and environments, including disposable protective [...]
Channel Therapeutics Announces Reverse Common Stock Split in Conjunction with the Close of the Merger with Pelthos Therapeutics and Concurrent $50.1 Million Private Placement
27/06/2025
FREEHOLD, N.J., June 27, 2025 (GLOBE NEWSWIRE) -- Channel Therapeutics Corporation, (“Channel” or the “Company”), (NYSE American: CHRO), an emerging leader in the development of non-opioid pain treatment therapeutics, [...]
Safety Shot Completes Acquisition of Yerbae Brands Corp.
27/06/2025
SCOTTSDALE, Ariz., June 27, 2025 (GLOBE NEWSWIRE) -- Yerbaé Brands Corp . (TSX-V: YERB.U; OTCQX: YERBF) (“ Yerbaé ”), a plant-based energy beverage company, and Safety Shot, Inc. (Nasdaq: SHOT) (“ SHOT ”, “ Safety Shot [...]
New Data for Nusinersen Underscore Biogen’s Commitment to Advancing Clinical Research to Improve Outcomes in SMA
27/06/2025
New analyses from DEVOTE Part C further characterize the improvements in motor function in participants with SMA who transitioned to the investigational higher dose regimen of nusinersen from 12 mg SPINRAZA ® ( [...]
Pharvaris Announces Clinical Trial Data Highlighting Deucrictibant for the Treatment of HAE to be Presented at the 2025 US HAEA National Summit
27/06/2025
ZUG, Switzerland, June 27, 2025 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to help address unmet needs of those living [...]
Eton Pharmaceuticals Announces Addition to Russell 2000® and Russell 3000® Indexes
27/06/2025
DEER PARK, Ill., June 27, 2025 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (“Eton” or the “Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare [...]
Tango Therapeutics Announces First Patient Dosed in Phase 1/2 Trial of TNG462 plus Revolution Medicines’ Daraxonrasib or Zoldonrasib in Patients with RAS-Mutant MTAP-deleted Pancreatic or Lung Cancer
27/06/2025
BOSTON, June 27, 2025 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ: TNGX), a clinical-stage biotechnology company committed to discovering the next generation of precision cancer medicines, today announced that [...]
BioCryst Announces Sale of European ORLADEYO® (berotralstat) Business to Neopharmed Gentili for up to $264 Million
27/06/2025
—Neopharmed Gentili will pay BioCryst $250 million upfront for the European assets and rights related to ORLADEYO, and up to $14 million in future milestones— —BioCryst plans to use proceeds to retire all remaining term [...]

Pages